6 Asia Pacific Cancer Vaccine Programs Attracting Global Clinical Investment in 2026
The Asia Pacific region's burden of cancer — accounting for 49 percent of global cancer deaths according to the 2026 GLOBOCAN update — combined with the simultaneous maturation of its clinical trial infrastructure, regulatory frameworks, and biomanufacturing capacity is creating the conditions for what oncology investors are now characterizing as the Asia Pacific cancer...
0 Commentarios 0 Acciones 123 Views 0 Vista previa